Who are Oxymetazoline 0.05% w/v's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xylocaine with Epinephrine, Experimental: Alpha-blocker group, Carvedilol alone, Continuous infusion of Norepinephrine, Visine® for Contacts®, brompheniramine + phenylephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxymetazoline-0-05-w-v.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oxymetazoline 0.05% w/v — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxymetazoline 0.05% w/v (Oxymetazoline 0.05% w/v) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist (nasal decongestant). Area: Otolaryngology / Respiratory.

marketed Alpha-1 adrenergic agonist (nasal decongestant) Alpha-1 adrenergic receptor Otolaryngology / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Oxymetazoline 0.05% w/v (Oxymetazoline 0.05% w/v) — Brian J Lipworth. Oxymetazoline is an alpha-1 adrenergic agonist that constricts blood vessels in the nasal mucosa, reducing nasal congestion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oxymetazoline 0.05% w/v TARGET	Oxymetazoline 0.05% w/v	Brian J Lipworth	marketed	Alpha-1 adrenergic agonist (nasal decongestant)	Alpha-1 adrenergic receptor
Xylocaine with Epinephrine	Xylocaine with Epinephrine	Vrije Universiteit Brussel	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors
Experimental: Alpha-blocker group	Experimental: Alpha-blocker group	Pedro de Figueiredo Buchalla	marketed	Alpha-blocker	Alpha-1 adrenergic receptor
Carvedilol alone	Carvedilol alone	Taipei Veterans General Hospital, Taiwan	marketed	Beta-blocker with alpha-1 antagonist activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Continuous infusion of Norepinephrine	Continuous infusion of Norepinephrine	Hassan II University	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor
Visine® for Contacts®	Visine® for Contacts®	Merck Sharp & Dohme LLC	marketed	Ophthalmic decongestant	Alpha-1 adrenergic receptor
brompheniramine + phenylephrine	brompheniramine + phenylephrine	Ache Laboratorios Farmaceuticos S.A.	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (phenylephrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist (nasal decongestant) class)

Association Asthma, Bulgaria · 1 drug in this class
Brian J Lipworth · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxymetazoline 0.05% w/v — Competitive Intelligence Brief. https://druglandscape.com/ci/oxymetazoline-0-05-w-v. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab